News

Video

AAO 2024: Energy drinks and central retinal vein occlusions

Key Takeaways

  • Energy drink consumption may be linked to central and branch retinal vein occlusions in young adults.
  • The study is expanding to include retinal hemorrhaging and aneurysms, indicating broader retinal health impacts.
SHOW MORE

Jonathan Brugger, MD, shared insights on the correlation of central retinal vein occlusions, or branch retinal vein occlusions, in young adults who consume numerous energy drinks.

Jonathan Brugger, MD, shared insights on the correlation of central retinal vein occlusions, or branch retinal vein occlusions, in young adults who consume numerous energy drinks.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Jonathan Brugger, MD:

Hi, I'm Dr Jonathan Brugger, a vitreoretinal surgeon in Charleston, South Carolina, with Carolina Eye Care Physicians, and I want to give an update about a cohort of patients that we're collecting and gathering data on. And these are some young adults, both male and female, who are presenting with central retinal vein occlusions, or branch retinal vein occlusions for no apparent cause.

Despite negative workups, we start to investigate their history, and we have determined that these individuals drank a lot of energy drinks. And this could be anything from Red Bull or Monster, and ultimately, those individuals were consuming maybe 2, 3 or 4 servings a day prior to their episode, and now we are treating those individuals. More recently, we are expanding the cohort to also include those with micro and macro aneurysms.

Again, in younger populations, individuals who may be naive to energy drinks are now consuming those and we are seeing some hemorrhaging of the retina. It's interesting now that as we look at macro aneurysms, we may want to explore asking older patients if they are indulging in energy drinks. We often label these with younger people trying to stay up later, trying to do all the good things. However, it could be possible that older patients, too, are indulging in these beverages. So, we are gathering these patients.

We're going to be looking at their outcomes and their presentations, as well as gathering their medical records from their primary care doctors of their behavioral changes to lower their blood pressure, as we know that vein occlusions are blood pressure driven.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.